NHS 6008 Discussion Reimbursement Recommendations

Want create site? With Free visual composer you can do it easy.

NHS 6008 Discussion Reimbursement Recommendations

NHS 6008 Discussion Reimbursement Recommendations

Given the topic you selected in the Unit 2 discussion, CMS
Regulations, complete the following:

Propose insights and recommendations to promote
reimbursement for services offered by the provider organization.

Discuss the implications for future supply and demand for
services provided.

Examples: A preventable fall results in non-payment to
provider; inaccurate coding or untimely claim submission results in payment
denial; or patient satisfaction scores deteriorate, and CMS denies payment for
provider services.

Post according to the Faculty Expectations Response
Guidelines. Remember to cite the readings, resources, and research that you
have used in the development of your post.

Response Guidelines

Respond to the posts of other learners according to the
Faculty Expectations Response Guidelines.

Offer additional insights and recommendations for promoting
reimbursement that you have observed or worked with from your own practice or
health care setting.

Offer additional implications of the current state of
reimbursement on future supply and demand within the scope of a health care
setting or health care practice role with which you are familiar.

In Europe and beyond, the rising costs of healthcare and limited healthcare resources have resulted in the implementation of health technology assessment (HTA) to inform health policy and reimbursement decision-making. European legislation has provided a harmonized route for the regulatory process with the European Medicines Agency, but reimbursement decision-making still remains the responsibility of each country. There is a recognized need to move toward a more objective and collaborative

Click here to ORDER an A++ paper from our Verified MASTERS and DOCTORATE WRITERS:NHS 6008 Discussion Reimbursement Recommendations

reimbursement environment for new medicines in Europe. Therefore, the aim of this study was to objectively assess and compare the national reimbursement recommendations of 9 European jurisdictions following European Medicines Agency (EMA) recommendation for centralized marketing authorization. Methods: Using publicly available data and newly developed classification tools, this study appraised 9 European reimbursement systems by assessing HTA processes and the relationship between the regulatory, HTA and decision-making organizations. Each national HTA agency was classified according to two novel taxonomies. The System taxonomy, focuses on the position of the HTA agency within the national reimbursement system according to the relationship between the regulator, the HTA-performing agency, and the reimbursement decision-making coverage body. The HTA Process taxonomy distinguishes between the individual HTA agency’s approach to economic and therapeutic evaluation and the inclusion of an independent appraisal step. The taxonomic groups were subsequently compared with national HTA recommendations. Results: This study identified European national reimbursement recommendations for 102 new active substances (NASs) approved by the EMA from 2008 to 2012. These reimbursement recommendations were compared using a novel classification tool and identified alignment between the organizational structure of reimbursement systems (System taxonomy) and HTA recommendations. However, there was less alignment between the HTA processes and recommendations. Conclusions: In order to move forward to a more harmonized HTA environment within Europe, it is first necessary to understand the variation in HTA practices within Europe. This study has identified alignment between HTA recommendations and the System taxonomy and one of the major implications of this study is that such alignment could support a more collaborative HTA environment in Europe.

Did you find apk for android? You can find new Free Android Games and apps.